Correspondingly, Topo1 inhibitor selectively eradicates Notch1-driven AtmKD/- leukemia, but not the isogenic parental Atm proficient leukemia, identifying Topo1 inhibitors as a targeted therapy for human cancers carrying missense ATM kinase domain mutations. Here, NOTCH1 is linked to leukemia.